U.S., July 11 -- ClinicalTrials.gov registry received information related to the study (NCT07059377) titled 'Semaglutide for Smoking Cessation in Patients With Diabetes' on April 30.
Brief Summary: To assess the feasibility of conducting a randomized controlled trial (RCT) to determine the effectiveness of semaglutide as an adjunct to combination NRT in supporting smoking cessation for patients with diabetes.
Study Start Date: July, 2025
Study Type: INTERVENTIONAL
Condition:
Diabetes Mellitus, Type 2
Nicotine Addiction
Tobacco Dependence
Intervention:
DRUG: Semaglutide
Starting dose will be 0.25mg once a week for 4 weeks, then titrated up to 0.5mg once a week. For those requiring additional blood sugar control, the dose may be titra...